A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)

Study summary

The aim of this study is to characterize the safety and tolerability of MORAb-202, and to assess the objective response rate in participants with previously treated, metastatic NSCLC AC.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedMORAb-202

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC) · Metastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Sep 4, 2025 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 2

Interventional

Where is it offered?33 U.S. locations

Locations may change over time.

Who runs it?Bristol-Myers Squibb

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 2
Sponsor: Bristol-Myers Squibb
Interventions being studied: Drug: MORAb-202

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Non-small cell lung cancer (NSCLC)→

Disease setting

Metastatic or stage IV→

Study topics

After prior treatment→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Histologically or cytologically documented metastatic NSCLC AC (as defined by the 8th International Association for the Study of Lung Cancer Classification).
Measurable target disease assessed by the investigator according to RECIST 1.1.
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1

Reasons someone may not be able to joinExclusion criteria

NSCLC histologies other than AC (ie, squamous cell carcinoma, large cell carcinoma).
Significant third-space fluid retention (eg, ascites or pleural effusion) that requires repeated drainage.
Prior pneumonectomy. Prior lobectomy and segmentectomy are allowed \> 12 months before treatment.
Recent chest radiotherapy. Participants with chest or chest wall radiation may be permitted if chest radiation is documented \> 6 months before starting study treatment. Other protocol-defined inclusion/

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Local Institution - 0007Orange, California
Local Institution - 0035Lone Tree, Colorado
Local Institution - 0043Clermont, Florida
Local Institution - 0010Orange City, Florida
Local Institution - 0001Marietta, Georgia
Local Institution - 0005Louisville, Kentucky
Local Institution - 0044Silver Spring, Maryland
Henry Ford HospitalDetroit, Michigan
Local Institution - 0002Kansas City, Missouri
Local Institution - 0011Charlotte, North Carolina
Local Institution - 0034Arlington, Texas
Local Institution - 0045Flower Mound, Texas

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 4, 2025. Always confirm current availability with the study team.

View original record ↗